Evidence review · from the 250-topic plan
GIP, explained: the disgraced hormone that became tirzepatide's edge
GIP — glucose-dependent insulinotropic polypeptide — spent decades as the incretin family's disappointment: discovered first, then written off when diabetic patients seemed resistant to it, with some research groups pursuing GIP blockers as seriously as boosters. Tirzepatide is the wager that the write-off was wrong — a single molecule agonizing GIP and GLP-1 receptors together — and the outcomes settled the bet at the scoreboard level: superiority over pure GLP-1 therapy in the head-to-head. What stays genuinely live is the mechanism question — how much each of GIP's proposed contributions (adipose effects, central appetite signaling, a tolerability assist) actually carries. This piece tells the redemption arc honestly: settled where it's settled, contested where it's contested.
The fall: how a hormone gets written off
GIP was the first incretin characterized — a gut hormone that tells the pancreas glucose is incoming — yet in type 2 diabetes its insulin-boosting effect looked blunted, and the field's verdict hardened into textbook: GLP-1 was the therapeutic incretin; GIP was the resistant one. The judgment ran deep enough that antagonism — blocking GIP — attracted real programs on the theory it might aid weight. When one target draws credible bets in both directions, the honest summary is that the biology was unresolved — worth remembering whenever anyone narrates receptor science as tidy.
The case for redemption
The rehabilitation argument assembled several threads: GIP receptors are abundant in adipose tissue, where signaling may improve fat-storage flexibility and metabolic handling; they populate appetite-relevant brain regions, suggesting central satiety effects additive to GLP-1's; rodent and mechanistic work hinted GIP activity might temper the nausea signaling that limits GLP-1 dosing — the tantalizing possibility that the second receptor buys efficacy headroom by making higher effective doses livable; and chronic agonism may functionally reset the very receptor resistance that fueled the write-off. Each thread had counter-readings — which is exactly why the argument needed a trial program rather than a review article.
The outcomes verdict
The trials answered at the only level that binds: the SURPASS program beat pure GLP-1 comparators on glucose and weight in diabetes; SURMOUNT-1 posted the class's landmark 15–20.9% staircase; and SURMOUNT-5 ran the direct duel — roughly 20.2% versus 13.7% against semaglutide at tolerated maximums. Whatever GIP is doing mechanistically, the dual-agonist package outperforms the single — that much moved from hypothesis to scoreboard. The careful phrasing matters: trials validate molecules, not mechanism narratives; tirzepatide won, and GIP is the leading explanation for why.
What stays contested — and why that's fine
Three live disputes keep mechanism sessions interesting: how much of the margin is GIP versus simply a different molecule's pharmacology; whether the tolerability-assist theory survives head-to-head adverse-event accounting (GI profiles ran broadly similar in SURMOUNT-5 — the assist, if real, may be buying efficacy rather than comfort); and what agonism-versus-antagonism both showing weight signals in different programs says about receptor biology nobody fully models yet. None of this unsettles the clinical result; all of it counsels humility about tidy explanations — including ours.
The shopper's translation
Three usable sentences fall out. The premium has a reason: the ~6.5-point average gap is the receptor bet paying off, and it's why the audited tirzepatide flat runs $20/month above the sema floor ($139 vs $119) — priced per point, still the field's best value spread. The mechanism isn't a menu: marketing that promises GIP's specific gifts (“better fat metabolism!”) is selling the contested part; buy the outcome data, not the pathway poetry. The certificate line holds: compounded tirzepatide intends the same dual agonist; the trial certificates belong to the product studied — same sentence as always, because it's always the sentence. The dual-agonist flat rate ↗
FAQ
What does GIP do in tirzepatide?
It's the second receptor: proposed contributions include adipose metabolic effects, additive central appetite signaling, and a tolerability assist — with the package's superiority proven in outcomes trials even as the mechanism split stays debated.
Why was GIP considered a failed hormone?
In type 2 diabetes its insulin-boosting effect appeared blunted — “GIP resistance” — enough that some programs pursued GIP blockers; chronic agonism appears to overcome the resistance, part of the redemption story.
Is tirzepatide better than semaglutide because of GIP?
Tirzepatide outperformed semaglutide head-to-head (~20.2% vs ~13.7%); GIP is the leading explanation, but trials certify molecules, not mechanism narratives.
Sources
- Incretin physiology reviews — GIP discovery, resistance literature, agonist/antagonist programs.
- SURPASS program; SURMOUNT-1; SURMOUNT-5 — the outcomes verdict.
- Mechanistic work on GIP receptors in adipose tissue and CNS; tolerability-interaction studies.